Yang et al. reported that serum sEVs from DOX- and PTX-resistant BC patients had higher levels of miR-378a-3p and miR-378d, and suggested a novel mechanism whereby DOX and PTX chemotherapy activated the EZH2/STAT3 pathway in BC cells and led to higher abundance of these miRNAs in serum sEVs [224]. The gene discussed is EZH2; the disease is breast cancer.